New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2014
07:09 EDTSGMO, BIIBBiogen and Sangamo collaborate for hemoglobinopathy treatment development
Biogen (BIIB) and Sangamo (SGMO) announced an exclusive worldwide collaboration and license agreement focused on the development of therapeutics for hemoglobinopathies, inherited conditions that result from the abnormal structure or underproduction of hemoglobin. Sangamo is responsible for all research and development activities, and both companies will perform activities to enable submission of an Investigational New Drug Application for SCD. Biogen will provide Sangamo with an upfront payment of $20M and will reimburse Sangamo for its internal and external research and development program-related costs. Sangamo may also receive additional payments of approximately $300M based on the achievement of certain milestones, as well as double digit royalties on product sales.
News For BIIB;SGMO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
10:58 EDTBIIBDeutsche Bank biotech analyst holds an analyst/industry conference call
Subscribe for More Information
May 20, 2015
07:10 EDTSGMOPiper Jaffray to hold a symposium
Subscribe for More Information
May 18, 2015
07:06 EDTSGMOSangamo presents new data from proprietary ZFP therapeutic programs
Subscribe for More Information
May 15, 2015
09:31 EDTBIIBAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
May 14, 2015
09:11 EDTSGMOSangamo updates HIV and cancer candidates results
Sangamo BioSciences announced clinical and preclinical data from several ZFP Therapeutic programs and collaborations demonstrating new evidence of viral control in HIV/AIDS. Two trials of the company's ZFP Therapeutic, SB-728-T, which is being developed as a potential 'functional cure' for HIV/AIDS, demonstrated the effect of SB-728-T treatment on both viral load control and HIV reservoir reduction in HIV-infected subjects. Data were also presented demonstrating the successful incorporation of ZFN-mediated genome editing into an existing clinical scale production method to improve the anti-tumor activity of a tumor infiltrating lymphocyte-based therapeutic for melanoma.
May 13, 2015
07:32 EDTBIIBBiogen names Matt Griffiths as CIO
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use